We report the case of a type 2 diabetes subject who developed severe leucopenia associated with treatment with the dipeptidil-peptidase 4 enzyme inhibitor Sitagliptin and highlights DPP4 inhibitors as a possible cause of unexplained hematolgical abnormalities in patients receiving DPP4-inhibitor treatment.
Pitocco, D., Zaccardi, F., Martini, F., Scavone, G., Musella, T., Caputo, S., Ghirlanda, G., Severe leucopenia associated with sitagliptin use, <<DIABETES RESEARCH AND CLINICAL PRACTICE>>, 2011; 91 (Febbraio): 30-32 [http://hdl.handle.net/10807/13833]
Severe leucopenia associated with sitagliptin use
Pitocco, Dario;Zaccardi, Francesco;Scavone, Giuseppe;Musella, Tittania;Caputo, Salvatore;Ghirlanda, Giovanni
2011
Abstract
We report the case of a type 2 diabetes subject who developed severe leucopenia associated with treatment with the dipeptidil-peptidase 4 enzyme inhibitor Sitagliptin and highlights DPP4 inhibitors as a possible cause of unexplained hematolgical abnormalities in patients receiving DPP4-inhibitor treatment.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
